TRUPMEDIUM SIGNALFINANCIAL10-K

TRUP demonstrated substantially improved cash generation from operations while maintaining solid revenue growth and strengthening its balance sheet position.

The company's operating cash flow expanded meaningfully, indicating improved operational efficiency and cash conversion from its growing pet insurance business. The reduction in total debt combined with increased stockholders' equity suggests management is strengthening the financial foundation while investing in growth opportunities.

Comparing 2026-02-13 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

TRUP delivered balanced financial performance with revenue growing 11.9% to $1.4B and gross profit expanding 26.4% to $64.9M, demonstrating improving operational leverage. The company's cash generation from operations grew substantially to $89.5M, more than offsetting increased capital expenditures of $14.1M. The balance sheet strengthened notably with debt reduction to $101.8M and stockholders' equity increasing 18.8% to $383.9M, while total assets expanded 13.4% to $915.0M, reflecting the company's continued investment in growth while maintaining financial discipline.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+85.3%
$48.3M→$89.5M

Operating cash flow surged 85.3% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
+45.4%
$9.7M→$14.1M

Capital expenditure jumped 45.4% — major investment cycle underway; assess returns on deployment.

Gross Profit
P&L
+26.4%
$51.4M→$64.9M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Debt
Balance Sheet
-20.2%
$127.5M→$101.8M

Debt reduced 20.2% — deleveraging strengthens balance sheet and reduces financial risk.

Stockholders Equity
Balance Sheet
+18.8%
$323.3M→$383.9M

Equity base grew 18.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
+17.2%
$349.6M→$409.8M

Current liabilities rose 17.2% — increased short-term obligations, watch current ratio.

Current Assets
Balance Sheet
+15.7%
$597.3M→$691.1M

Current assets grew 15.7% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
-13.9%
$160.3M→$138.0M

Cash decreased 13.9% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
+13.4%
$806.9M→$915.0M

Asset base grew 13.4% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
+11.9%
$1.3B→$1.4B

Revenue growing 11.9% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-02-27
ADDED
As of February 6, 2026, there were approximately 43,430,169 shares of the registrant s common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 7A.
contains forward-looking statements within the meaning of the federal securities laws.
All statements other than statements of historical fact are forward-looking statements.
Through our data-driven, vertically-integrated approach, we develop and offer high-value medical insurance products, priced to take into account each pet s unique characteristics and coverage level.
Within this segment we also offer products in certain countries in Continental Europe which are currently underwritten by third parties who pay us commissions that we recognize as revenue.
Our other business segment generates revenue from other product offerings, primarily by underwriting policies on behalf of third parties with whom we generally have a business-to-business relationship.
The largest source of revenue within this segment is from our long-standing contractual relationship as an underwriter for Pets Best Insurance Services ("Pets Best"), a third-party insurance provider we have worked with since 2015.
We expect that enrollment from Pets Best will continue to decline as it engages other third-party underwriters.
Department of Veterans Affairs program and employer-sponsored programs, primarily for companies with animal health related operations.
REMOVED
As of February 19, 2025, there were approximately 42,490,664 shares of the registrant s common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 7A.
All statements contained in this Annual Report on Form 10-K other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.
Through our data-driven, vertically-integrated approach, we develop and offer high value medical insurance products, priced specifically for each pet s unique characteristics and coverage level.
Within this segment we also offer products in certain countries in Continental Europe which are currently underwritten using third-party underwriters.
Going forward our intent is to assume full insurance risk for these products, either through direct underwriting or reinsurance arrangements.
Our other business segment is comprised of revenue from other product offerings with third parties with whom we generally have a business-to-business relationship.
The largest source of revenue within this segment is from our long-standing contractual relationship with Pets Best Insurance Services ("Pets Best"), a third-party partner we have worked with since 2015.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →